Journal Article

Pharmacological therapy for hypertrophic cardiomyopathy: what is the evidence for success?

L. Rydén and F. Gadler

in European Heart Journal Supplements

Published on behalf of European Society of Cardiology

Volume 3, issue suppl_L, pages L21-L25
Published in print October 2001 | ISSN: 1520-765X
Published online October 2001 | e-ISSN: 1554-2815 | DOI:
Pharmacological therapy for hypertrophic cardiomyopathy: what is the evidence for success?

Show Summary Details


The available experience from studies of pharmacological treatment of patients with hypertrophic cardiomyopathy was mainly gained in selected patient samples, with severe symptoms or a complicated clinical setting. Moreover, most reports on drug efficacy are based on either acute mechanistic studies or non-controlled patient cohorts, which are usually rather restricted in numbers and followed for limited periods of time. Bearing in mind the symptomatic presentation of hypertrophic cardiomyopathy, which is sometimes highly variable and influenced to a degree by sympathetic arousal, it is understandable that a considerable placebo effect may occur when initiating any type of treatment. Considering the pathophysiology that underlies symptoms of hypertrophic cardiomyopathy, it is not surprising that the pharmacological agents that are most advocated are beta-blockers and calcium channel blockers - drugs that impact on several of the factors that are responsible for the symptoms. Other compounds that may be used include antiarrhythmic drugs, of which disopyramide - combining antiarrhythmic with negative inotropic properties - has attracted particular interest.

Keywords: Treatment; pharmacological; cardiomyopathy; hypertrophic; symptoms; evidence

Journal Article.  0 words. 

Subjects: Cardiovascular Medicine

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.